CN Patent

CN102558352A — 针对表皮生长因子受体的缺失突变体的抗体及其使用

Assigned to Amgen Fremont Inc · Expires 2012-07-11 · 14y expired

What this patent protects

本发明涉及新颖抗体，尤其涉及针对表皮生长因子受体的缺失突变体的抗体，而且尤其涉及III型缺失突变体EGFRvIII。本发明也涉及针对表皮生长因子受体的缺失突变体的人类单克隆抗体，而且尤其为EGFRvIII。本发明也提供这些抗体的诊断和治疗調配物，及其免疫偶联物。

USPTO Abstract

本发明涉及新颖抗体，尤其涉及针对表皮生长因子受体的缺失突变体的抗体，而且尤其涉及III型缺失突变体EGFRvIII。本发明也涉及针对表皮生长因子受体的缺失突变体的人类单克隆抗体，而且尤其为EGFRvIII。本发明也提供这些抗体的诊断和治疗調配物，及其免疫偶联物。

Drugs covered by this patent

Patent Metadata

Patent number
CN102558352A
Jurisdiction
CN
Classification
—
Expires
2012-07-11
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Fremont Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.